What Crystagen is
Crystagen is a commercial “peptide bioregulator” name associated with the tetrapeptide EDGQ. A patent and laboratory literature describe proposed immune or aging effects, but patents are ownership documents—not clinical evidence or regulatory approval.
Evidence is preclinical
Published research measured molecular markers in aging spleen models and inflammatory responses in human cell cultures.[1][2] Teloryx found no controlled human trial establishing improved immunity, infection resistance, vaccine response, cancer outcomes, or healthy longevity.
Safety is unknown
No human dose-response, pharmacokinetic, adverse-event, immunogenicity, autoimmune-disease, pregnancy, cancer, or long-term safety program exists. Immune-marker changes cannot automatically be assumed beneficial.
Regulatory status
Crystagen is not FDA-approved. Compounded drugs are not premarket-verified for safety, effectiveness, or quality.[3] Teloryx publishes no dose or preparation protocol.